An Evidence-Based Practice Approach to Evaluating Biotechnologically Derived Medications

Abstract

Recent advances in pharmaceutical biotechnology have led to the development of many different therapeutic proteins. These technologies have given credence to the legitimate promise that we, at some point, may be able to more closely match some specific patients with the most effective and safe drugs at an individualized dose—personalized/precision medicine. Importantly, these therapeutic proteins should be incorporated into clinical practice just like any other treatment option, which is by using the best available evidence and balancing benefits and harms.